Activation of the p38 Map Kinase Pathway is Essential for the Antileukemic Effects of Dasatinib

Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cellular events leading to generation of its potent a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Dumka, Disha, Puri, Poonam, Carayol, Nathalie, Lumby, Crystal, Balachandran, Harikrishnan, Schuster, Katja, Verma, Amit K, Terada, Lance S, Platanias, Leonidas C., Parmar, Simrit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2888505/
https://ncbi.nlm.nih.gov/pubmed/19672773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428190903147637
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia